The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
25 11 2020
Historique:
received: 10 09 2020
revised: 20 11 2020
accepted: 23 11 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 7 2 2021
Statut: epublish

Résumé

Rare disease (RD) registries are important platforms that facilitate communication between health care professionals, patients and other members of the multidisciplinary team. RD registries enable data sharing and promotion of research and audits, often in an international setting, with the overall aim of improving patient care. RD registries also have a fundamental role in supporting the work of clinical networks such as the European Reference Networks (ERNs) for rare diseases. With the recent expansion of RD registries, it has become even more essential to outline standards of good practice in relation to governance, infrastructure, documentation, training, audits and adopting the Findable, Accessible, Interoperable and Reusable (FAIR) data principles to maintain registries of high quality. For the purpose of this paper, we highlight vital aspects of data access and data governance policies for RD registries, using the European Registries for Rare Endocrine Conditions (EuRRECa) as an example of a project that aims to promote good standards of practice for improving the quality of utilization of RD registries.

Identifiants

pubmed: 33255540
pii: ijerph17238743
doi: 10.3390/ijerph17238743
pmc: PMC7727867
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Genes (Basel). 2019 Nov 27;10(12):
pubmed: 31783696
Eur J Endocrinol. 2019 Jan 1;180(1):89-98
pubmed: 30407922
Int J Environ Res Public Health. 2018 Aug 03;15(8):
pubmed: 30081484
BMC Med Ethics. 2020 Feb 3;21(1):12
pubmed: 32013947
Public Health Genomics. 2016;19(2):108-15
pubmed: 26998603

Auteurs

Salma R Ali (SR)

Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow G51 4TF, UK.
Office for Rare Conditions, University of Glasgow, Glasgow G51 4TF, UK.

Jillian Bryce (J)

Office for Rare Conditions, University of Glasgow, Glasgow G51 4TF, UK.

Li En Tan (LE)

Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow G51 4TF, UK.

Olaf Hiort (O)

Department of Paediatrics and Adolescent Medicine, Division of Paediatric Endocrinology and Diabetes, University of Lübeck, 23562 Lübeck, Germany.

Alberto M Pereira (AM)

Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Erica L T van den Akker (ELT)

Department of Pediatrics, Division of Pediatric Endocrinology, Erasmus MC-Sophia Children's Hospital, 3000 CB Rotterdam, The Netherlands.
Obesity Center CGG, Erasmus MC-Sophia Children's Hospital, 3000 CB Rotterdam, The Netherlands.

Natasha M Appelman-Dijkstra (NM)

Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Jerome Bertherat (J)

Reference Center for Rare Adrenal Disorders, Cochin Hospital, Université de Paris, 75006 Paris, France.

Martine Cools (M)

Department of Internal Medicine and Paediatrics, Ghent University, 9000 Ghent, Belgium.
Department of Paediatric Endocrinology, Ghent University Hospital, 9000 Ghent, Belgium.

Olaf M Dekkers (OM)

Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Departments of Medicine & Clinical Epidemiology, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands.

Yllka Kodra (Y)

National Centre for Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Luca Persani (L)

Division of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, 20145 Milan, Italy.
Department of Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.

Arelene Smyth (A)

Office for Rare Conditions, University of Glasgow, Glasgow G51 4TF, UK.

Christopher Smythe (C)

Office for Rare Conditions, University of Glasgow, Glasgow G51 4TF, UK.

Domenica Taruscio (D)

National Centre for Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

S Faisal Ahmed (SF)

Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow G51 4TF, UK.
Office for Rare Conditions, University of Glasgow, Glasgow G51 4TF, UK.
Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH